首页 > 最新文献

Cancer discovery最新文献

英文 中文
SLAMF6 Restrains T-Cell Function and Limits Antitumor Immunity. SLAMF6抑制t细胞功能并限制抗肿瘤免疫
IF 28.2 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.cd-rw2026-028
{"title":"SLAMF6 Restrains T-Cell Function and Limits Antitumor Immunity.","authors":"","doi":"10.1158/2159-8290.cd-rw2026-028","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-rw2026-028","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"42 1","pages":"OF1"},"PeriodicalIF":28.2,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147346297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptomic Subtypes Are Associated with Clinical Outcomes for Patients with Lung Adenocarcinoma Who Have Never Smoked. 转录组亚型与从未吸烟的肺腺癌患者的临床结果相关
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-25-2137
Alexander A Azizi, Tej Pandya, Charles Swanton

Lung adenocarcinoma arising in individuals who have never smoked is understudied, represents a substantial global health burden, and is genomically distinct from smoking-associated disease. Zhao and colleagues have identified transcriptomic subtypes with prognostic value, including in stage I disease, supporting phenotypic state as an important determinant of outcome for lung adenocarcinoma in individuals who have never smoked. See related article by Zhao et al., p. 460.

从未吸烟的人发生的肺腺癌尚未得到充分研究,这是一项重大的全球健康负担,并且在基因组上不同于吸烟相关疾病。Zhao及其同事已经确定了具有预后价值的转录组亚型,包括在I期疾病中,支持表型状态是从未吸烟的个体肺腺癌预后的重要决定因素。参见赵等人的相关文章,第460页。
{"title":"Transcriptomic Subtypes Are Associated with Clinical Outcomes for Patients with Lung Adenocarcinoma Who Have Never Smoked.","authors":"Alexander A Azizi, Tej Pandya, Charles Swanton","doi":"10.1158/2159-8290.CD-25-2137","DOIUrl":"10.1158/2159-8290.CD-25-2137","url":null,"abstract":"<p><p>Lung adenocarcinoma arising in individuals who have never smoked is understudied, represents a substantial global health burden, and is genomically distinct from smoking-associated disease. Zhao and colleagues have identified transcriptomic subtypes with prognostic value, including in stage I disease, supporting phenotypic state as an important determinant of outcome for lung adenocarcinoma in individuals who have never smoked. See related article by Zhao et al., p. 460.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"423-425"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Plasticity Cell State Drives Lung Cancer Progression and Drug Resistance. 高可塑性细胞状态驱动肺癌进展和耐药
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-RW2026-018
{"title":"High-Plasticity Cell State Drives Lung Cancer Progression and Drug Resistance.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-018","DOIUrl":"10.1158/2159-8290.CD-RW2026-018","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Legacy of Mentorship: A Tribute to Lewis Cantley. 导师的遗产:向刘易斯·坎特利致敬。
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-25-1792
Heather R Christofk, Gina M DeNicola, Brooke M Emerling, Jeffrey A Engelman, David A Fruman, Marcus D Goncalves, Katja A Lamia, Costas A Lyssiotis, Brendan D Manning, Reuben J Shaw, Alex Toker, Matthew G Vander Heiden, Michael B Yaffe
{"title":"A Legacy of Mentorship: A Tribute to Lewis Cantley.","authors":"Heather R Christofk, Gina M DeNicola, Brooke M Emerling, Jeffrey A Engelman, David A Fruman, Marcus D Goncalves, Katja A Lamia, Costas A Lyssiotis, Brendan D Manning, Reuben J Shaw, Alex Toker, Matthew G Vander Heiden, Michael B Yaffe","doi":"10.1158/2159-8290.CD-25-1792","DOIUrl":"https://doi.org/10.1158/2159-8290.CD-25-1792","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"431-438"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newly Described Cell Death Pathway May Provide Therapeutic Opportunity. 新描述的细胞死亡途径可能提供治疗机会。
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-RW2026-010
{"title":"Newly Described Cell Death Pathway May Provide Therapeutic Opportunity.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-010","DOIUrl":"10.1158/2159-8290.CD-RW2026-010","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146060227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Legacy of Enduring Discovery. 持久发现的遗产。
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-25-1758
Lewis C Cantley
{"title":"A Legacy of Enduring Discovery.","authors":"Lewis C Cantley","doi":"10.1158/2159-8290.CD-25-1758","DOIUrl":"https://doi.org/10.1158/2159-8290.CD-25-1758","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"419-420"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML. 早期驱动者,晚期旁观者:DNMT3A R882突变在人类AML中揭示的阶段特异性作用
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-25-2277
Yubin Zhou, Yun Huang

In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis. See related article by Köhnke et al., p. 592.

在这一期中,Köhnke、Karigane及其同事在人类急性髓性白血病样本中应用等位基因特异性CRISPR/Cas9校正来剖析DNA甲基转移酶3A (DNMT3A)精氨酸882 (R882)突变的分期特异性功能。他们证明,DNMT3A R882突变是维持白血病前期细胞自我更新和炎症程序所必需的,但一旦白血病建立,它在很大程度上是可缺性的,同时仍然影响白血病干细胞的频率,从而为重新考虑在白血病发生早期靶向DNMT3A突变克隆的治疗窗口提供了强有力的临床前理论依据。参见Köhnke等人的相关文章,第592页。
{"title":"Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.","authors":"Yubin Zhou, Yun Huang","doi":"10.1158/2159-8290.CD-25-2277","DOIUrl":"10.1158/2159-8290.CD-25-2277","url":null,"abstract":"<p><p>In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis. See related article by Köhnke et al., p. 592.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"428-430"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthetic Storage of Transcripts Captures Hidden States Driving Drug Resistance. 转录本的合成存储捕获驱动耐药性的隐藏状态。
IF 33.3 1区 医学 Q1 ONCOLOGY Pub Date : 2026-03-02 DOI: 10.1158/2159-8290.CD-RW2026-017
{"title":"Synthetic Storage of Transcripts Captures Hidden States Driving Drug Resistance.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-017","DOIUrl":"10.1158/2159-8290.CD-RW2026-017","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized mRNA Vaccine Spurs Lasting Immunity in TNBC 个性化mRNA疫苗刺激TNBC持续免疫
IF 28.2 1区 医学 Q1 ONCOLOGY Pub Date : 2026-02-27 DOI: 10.1158/2159-8290.cd-nw2026-0019
In a small adjuvant trial of patients with early-stage triple-negative breast cancer, a personalized mRNA neoantigen vaccine induced robust, multitarget T-cell responses that persisted for years. Notably, the vaccine was administered on its own, without concurrent chemotherapy or checkpoint blockade, highlighting the treatment’s stand-alone potential to drive durable antitumor immunity.
在一项针对早期三阴性乳腺癌患者的小型辅助试验中,一种个性化的mRNA新抗原疫苗诱导了持续多年的强效多靶点t细胞反应。值得注意的是,该疫苗是单独使用的,不需要同时进行化疗或检查点阻断,这突出了该治疗在驱动持久抗肿瘤免疫方面的独立潜力。
{"title":"Personalized mRNA Vaccine Spurs Lasting Immunity in TNBC","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0019","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0019","url":null,"abstract":"In a small adjuvant trial of patients with early-stage triple-negative breast cancer, a personalized mRNA neoantigen vaccine induced robust, multitarget T-cell responses that persisted for years. Notably, the vaccine was administered on its own, without concurrent chemotherapy or checkpoint blockade, highlighting the treatment’s stand-alone potential to drive durable antitumor immunity.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"1 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147314848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“Pioneering” p53 Reactivator Shows Proof-of-Concept in Phase I Trial “开创性”p53再激活剂在I期试验中显示概念验证
IF 28.2 1区 医学 Q1 ONCOLOGY Pub Date : 2026-02-27 DOI: 10.1158/2159-8290.cd-nw2026-0020
Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ineffective in tumors with KRAS mutations, and whether the strategy can be applied to more common missense mutations remains unclear, the findings offer proof of concept for p53 reactivation.
一项I期研究的结果表明,p53再激活剂rezatapopt是安全的,可以在一系列含有Y220C突变的实体瘤患者中引起反应。尽管该药物对KRAS突变的肿瘤无效,并且该策略是否适用于更常见的错义突变仍不清楚,但该发现为p53再激活的概念提供了证据。
{"title":"“Pioneering” p53 Reactivator Shows Proof-of-Concept in Phase I Trial","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0020","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0020","url":null,"abstract":"Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ineffective in tumors with KRAS mutations, and whether the strategy can be applied to more common missense mutations remains unclear, the findings offer proof of concept for p53 reactivation.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"67 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147314847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer discovery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1